These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38479614)

  • 1. Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
    Ma AT; Solé C; Juanola A; Escudé L; Napoleone L; Avitabile E; Pérez-Guasch M; Carol M; Pompili E; Gratacós-Ginés J; Soria A; Rubio AB; Cervera M; Moreta MJ; Morales-Ruiz M; Solà E; Poch E; Fabrellas N; Graupera I; Pose E; Ginès P
    J Hepatol; 2024 Sep; 81(3):441-450. PubMed ID: 38479614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
    Flamm SL; Wong F; Ahn J; Kamath PS
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2707-2716. PubMed ID: 36075500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.
    Patidar KR; Belcher JM; Regner KR; St Hillien SA; Simonetto DA; Asrani SK; Neyra JA; Sharma P; Velez JCQ; Wadei H; Nadim MK; Chung RT; Seethapathy R; Parada XV; Ouyang T; Ufere NN; Robinson JE; McLean Diaz P; Wilechansky RM; Przybyszewski EM; Smith TN; Ali AA; Orman ES; Schulz P; Siddiqui SM; Shabbir R; Liu LJ; Cama-Olivares A; Flannery AH; Baker ML; Gunasekaran D; Aswine A; Issa R; Li J; Verma S; Chalmers D; Varghese V; Lam W; Mohamed M; Kovacic R; Gaddy A; Attieh RM; Cortes P; Semnani S; Wang L; Khemichian S; Allegretti AS;
    J Hepatol; 2023 Dec; 79(6):1408-1417. PubMed ID: 37517455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study.
    Kulkarni AV; Ravikumar ST; Tevethia H; Premkumar M; Kumar K; Sharma M; Gupta R; Rao PN; Reddy DN
    Sci Rep; 2022 Apr; 12(1):5503. PubMed ID: 35365736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population.
    Reddy KR; Weinberg EM; Gonzalez SA; Izzy MJ; Simonetto DA; Frederick RT; Rubin RA; Fricker Z; Ikahihifo-Bender J; Harte M; Garcia S; Campbell K; Olofson A; Razavi RF; James JM; Patel H; Kim-Lee G; Witkiewicz S; Tobin W; Jamil K
    Liver Transpl; 2024 Oct; 30(10):1026-1038. PubMed ID: 38771635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management.
    Erstad BL
    Ann Pharmacother; 2024 Feb; 58(2):156-164. PubMed ID: 37271967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
    Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
    Ripoll C; Platzer S; Franken P; Aschenbach R; Wienke A; Schuhmacher U; Teichgräber U; Stallmach A; Steighardt J; Zipprich A;
    Trials; 2023 Apr; 24(1):258. PubMed ID: 37020315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
    Premkumar M; Kajal K; Reddy KR; Izzy M; Kulkarni AV; Duseja AK; Sihag KB; Divyaveer S; Gupta A; Taneja S; De A; Verma N; Rathi S; Bhujade H; Chaluvashetty SB; Roy A; Kumar V; Siddhartha V; Singh V; Bahl A
    Hepatology; 2024 May; 79(5):1048-1064. PubMed ID: 37976391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study on clinical outcomes of combination of terlipressin and albumin in Hepatorenal Syndrome.
    Krishna R; Raj J; Dev D; Prasad SC; Reghu R; V SO
    Scand J Gastroenterol; 2020 Jul; 55(7):860-864. PubMed ID: 32634332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
    Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
    Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury.
    Gambino C; Piano S; Stenico M; Tonon M; Brocca A; Calvino V; Incicco S; Zeni N; Gagliardi R; Cosma C; Zaninotto M; Burra P; Cillo U; Basso D; Angeli P
    Hepatology; 2023 May; 77(5):1630-1638. PubMed ID: 36125403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
    Nguyen-Tat M; Götz E; Scholz-Kreisel P; Ahrens J; Sivanathan V; Schattenberg J; Rey JW; Wörns MA; Galle PR; Marquardt JU
    Dtsch Med Wochenschr; 2015 Jan; 140(2):e21-6. PubMed ID: 25612289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Versus Standard Initiation of Terlipressin for Acute Kidney Injury in ACLF: A Randomized Controlled Trial (eTerli Study).
    Jindal A; Singh H; Kumar G; Arora V; Sharma MK; Maiwall R; Rajan V; Tewathia HV; Vasishtha C; Sarin SK
    Dig Dis Sci; 2024 Jun; 69(6):2204-2214. PubMed ID: 38637454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. End-stage liver disease: Management of hepatorenal syndrome.
    Mauro E; Garcia-Olveira L; Gadano A
    Liver Int; 2021 Jun; 41 Suppl 1():119-127. PubMed ID: 34155791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
    J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
    Narahara Y; Kanazawa H; Sakamoto C; Maruyama H; Yokosuka O; Mochida S; Uemura M; Fukui H; Sumino Y; Matsuzaki Y; Masaki N; Kokubu S; Okita K
    J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.